How Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration

• Amgen recently announced that its Board of Directors declared a US$2.52 per share dividend for the third quarter of 2026, payable on September 11, 2026 to shareholders of record as of August 21, 2026.
• Separately, the European Medicines Agency’s CHMP issued a positive opinion on expanding Repatha’s use to high‑risk adults without prior heart attack or stroke, potentially broadening its clinical role in cardiovascular prevention.
• We’ll now explore how the CHMP’s positive opinion on expanding Repatha’s cardiovascular indication could influence Amgen’s broader investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Amgen Investment Narrative Recap

To own Amgen, you need to believe its diversified drug portfolio and pipeline can sustain meaningful cash generation despite pricing pressure and biosimilar competition. Near term, the key catalyst is upcoming earnings and any updates on portfolio performance, while the biggest risk remains ongoing drug price pressure and loss of exclusivity in core franchises. The CHMP’s positive view on Repatha could be supportive, but it does not fundamentally change that central risk.

Among recent developments, the reaffirmed US$2.52 per share dividend for Q3 2026 stands out as directly relevant. It underlines Amgen’s ongoing commitment to returning cash to shareholders at a time when investors are watching how increased R&D spending, manufacturing investment, and patent challenges will affect cash flows. That consistency may matter as the market weighs the potential impact of an expanded Repatha label alongside broader questions around pricing and competitive pressure.

Yet against this steady dividend story, investors should still be aware of how intensifying global efforts to regulate and cap drug prices could...

Read the full narrative on Amgen (it's free!)

Amgen's narrative projects $40.1 billion revenue and $9.9 billion earnings by 2029.

Uncover how Amgen's forecasts yield a $352.23 fair value, a 9% downside to its current price.

Exploring Other Perspectives

While the baseline view focuses on pricing pressure and biosimilars, the most optimistic analysts were already assuming about US$44.4 billion of revenue and US$13.2 billion of earnings by 2029, so this Repatha news could either reinforce or challenge those expectations depending on how you think the story evolves from here.

Explore 5 other fair value estimates on Amgen - why the stock might be worth 9% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com